公开(公告)号：US20050271635A1

公开(公告)日：2005-12-08

申请号：US11196990

申请日：2005-08-04

申请人： Bradley Kropp ,  Earl Cheng ,  Yuan Zhang ,  Rick Cowan ,  Peter Moore

发明人： Bradley Kropp ,  Earl Cheng ,  Yuan Zhang ,  Rick Cowan ,  Peter Moore

IPC分类号： A61F2/02 ,  A61K35/12 ,  C12N5/071 ,  A61K45/00

CPC分类号： C12N5/0684 ,  A61F2/02 ,  A61K35/12 ,  C12N2502/1347 ,  C12N2502/23 ,  C12N2533/92

摘要： A method for providing a urinary tract tissue graft composition includes providing a tissue culture frame and a segment of small intestinal submucosa and positioning the segment of small intestinal submucosa in the tissue culture frame such that the segment of small intestinal submucosa is suspended and held in a taut position by the tissue culture frame. Smooth muscle and urothelial cells are isolated from a tissue specimen of a subject and cultured, and then seeded upon the segment of small intestinal submucosa, thereby forming a urinary tract tissue graft. A tissue culture frame in which such a urinary tract tissue graft may be formed is also disclosed.

摘要翻译： 提供尿道组织移植组合物的方法包括提供组织培养框架和小肠粘膜下层的一部分，并将小肠粘膜下层的部分定位在组织培养框架中，使得小肠粘膜下层的部分被悬浮并保持在 由组织培养框架拉紧位置。 从受试者的组织标本中分离平滑肌和尿路上皮细胞并培养，然后接种在小肠粘膜下层的段上，从而形成尿道组织移植物。 还公开了可以形成这种尿道组织移植物的组织培养框架。

公开(公告)号：US20030216811A1

公开(公告)日：2003-11-20

申请号：US10428350

申请日：2003-05-02

发明人： Stephen F. Badylak

IPC分类号： A61F002/44 ,  A61F002/06

CPC分类号： C12N5/0697 ,  A61K35/12 ,  C12N5/069 ,  C12N2501/135 ,  C12N2501/15 ,  C12N2501/165 ,  C12N2502/1347 ,  C12N2502/23 ,  C12N2502/28 ,  C12N2509/00

摘要： An intestinal submucosa tissue graft construct for use in repairing diseased or damaged tissues is provided. The graft construct comprises vertebrate intestinal submucosa tissue, added endothelial cells, and at least one additional preselected, exogenous population of cells which enhances initiation of the formation of vessel-like structures in the graft. The preselected population of cells can be a population of non-keratinized or keratinized epithelial cells or a population of mesodermally derived cells selected from the group consisting of fibroblasts, smooth muscle cells, skeletal muscle cells, cardiac muscle cells, multi-potential progenitor cells, pericytes, osteogenic cells, and any other suitable cell type, preferably selected based on the tissue to be repaired. Methods for enhancing the vascularization in vivo of these intestinal submucosa tissue graft constructs and for preparing these graft constructs are also provided.

摘要翻译： 提供用于修复患病或受损组织的肠粘膜下组织移植物构建体。 移植物构建体包括脊椎动物肠粘膜下层组织，添加的内皮细胞和至少一种额外的预选的外源细胞群，其增强移植物中血管样结构形成的起始。 预选的细胞群可以是非角化角化角化细胞或角化细胞上皮细胞群或选自成纤维细胞，平滑肌细胞，骨骼肌细胞，心肌细胞，多潜能祖细胞， 周细胞，成骨细胞和任何其它合适的细胞类型，优选基于待修复的组织选择。 还提供了用于增强这些肠粘膜下层组织移植物构建体的体内血管形成和用于制备这些移植物构建体的方法。

公开(公告)号：US20030165474A1

公开(公告)日：2003-09-04

申请号：US10314799

申请日：2002-12-06

发明人： Bradley P. Kropp ,  Yuan Yuan Zhang ,  Earl Y. Cheng ,  H.K. Lin ,  Rick Cowan

IPC分类号： C12N005/00

CPC分类号： A61K35/38 ,  A61F2/02 ,  A61K35/12 ,  A61L27/3629 ,  A61L27/3679 ,  A61L27/3813 ,  A61L27/3826 ,  A61L27/383 ,  A61L27/3882 ,  A61L27/3886 ,  A61L2430/22 ,  C12N5/0684 ,  C12N5/0685 ,  C12N2502/23 ,  C12N2533/92

摘要： A method for repairing damaged or diseased urinary tract tissue includes providing a urinary tract tissue graft composition that includes a distal ileal segment of small intestinal submucosa. The distal ileal segment of small intestinal submucosa may be utilized as an unseeded tissue graft composition, or the distal ileal segment of small intestinal submucosa may be positioned in a tissue culture frame, and smooth muscle and urothelial cells isolated from a tissue specimen of a subject and cultured are then seeded upon the distal ileal segment of small intestinal submucosa, thereby forming a urinary tract tissue graft.

公开(公告)号：US4423145A

公开(公告)日：1983-12-27

申请号：US261086

申请日：1981-05-07

申请人： Martha R. Stampfer ,  Helene S. Smith ,  Adeline J. Hackett

发明人： Martha R. Stampfer ,  Helene S. Smith ,  Adeline J. Hackett

IPC分类号： C12N5/071 ,  G01N33/50 ,  C12Q1/18 ,  C12N5/00 ,  C12R1/91

CPC分类号： C12N5/0631 ,  G01N33/5014 ,  C12N2501/01 ,  C12N2501/33 ,  C12N2502/23 ,  C12N2502/253 ,  C12N2503/02 ,  C12N2509/00 ,  Y10S435/948

摘要： Methods are disclosed for isolating and culturing human mammary epithelial cells of both normal and malignant origin. Tissue samples are digested with a mixture including the enzymes collagenase and hyaluronidase to produce clumps of cells substantially free from stroma and other undesired cellular material. Growing the clumps of cells in mass culture in an enriched medium containing particular growth factors allows for active cell proliferation and subculture. Clonal culture having plating efficiencies of up to 40% or greater may be obtained using individual cells derived from the mass culture by plating the cells on appropriate substrates in the enriched media. The clonal growth of cells so obtained is suitable for a quantitative assessment of the cytotoxicity of particular treatment. An exemplary assay for assessing the cytotoxicity of the drug adriamycin is presented.

摘要翻译： 公开了用于分离和培养正常和恶性起源的人乳腺上皮细胞的方法。 用包含酶胶原酶和透明质酸酶的混合物消化组织样品以产生基本上不含基质和其它不需要的细胞材料的细胞团。 在含有特定生长因子的富集培养基中将大量培养物中的细胞团生长允许活性细胞增殖和传代培养。 具有高达40％以上的电镀效率的克隆培养物可以使用通过在富集培养基中的适当底物上电镀细胞从源自大规模培养物的个体细胞获得。 如此获得的细胞的克隆生长适合于特定治疗的细胞毒性的定量评估。 提出了用于评估药物阿霉素的细胞毒性的示例性测定法。

公开(公告)号：US20240301360A1

公开(公告)日：2024-09-12

申请号：US18662599

申请日：2024-05-13

申请人： Regents of the University of Minnesota

发明人： Caleb Darwin Vogt ,  Angela Panoskaltsis-Mortari

IPC分类号： C12N5/071 ,  B33Y10/00 ,  B33Y30/00 ,  B33Y80/00 ,  C12N5/00

CPC分类号： C12N5/0697 ,  B33Y10/00 ,  B33Y30/00 ,  B33Y80/00 ,  C12N5/0062 ,  C12N2502/1347 ,  C12N2502/23 ,  C12N2502/28 ,  C12N2533/54

摘要： Devices, systems, and techniques are described for printing pre-aligned microtissues into larger tissue constructs. For example, a method of printing a tissue construct includes aligning cells in a first direction to create pre-aligned microtissues, suspending the pre-aligned microtissues in a liquid to create a bioink, and depositing the pre-aligned microtissues in a second direction to create the tissue construct.

公开(公告)号：US20240200036A1

公开(公告)日：2024-06-20

申请号：US18156726

申请日：2024-03-08

申请人： Children's Hospital Medical Center

发明人： James M. Wells ,  Carey Lane Watson ,  Jorge Orlando Munera ,  Maxime Mickael Mahe ,  Michael A. Helmrath ,  Michael J. Workman

IPC分类号： C12N5/071 ,  A01K67/0271 ,  G01N33/50

CPC分类号： C12N5/0679 ,  A01K67/0271 ,  C12N5/0697 ,  G01N33/5073 ,  A01K2227/105 ,  A01K2227/30 ,  A01K2267/03 ,  C12N2501/10 ,  C12N2501/11 ,  C12N2501/119 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/345 ,  C12N2501/385 ,  C12N2501/415 ,  C12N2501/727 ,  C12N2502/08 ,  C12N2502/23 ,  C12N2503/00 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2513/00

摘要： Disclosed are methods for making a vascularized hollow organ derived from human intestinal organoid (HIOs). The HIOs may be obtained from human embryonic stem cells (ESC's) and/or induced pluripotent stem cells (iPSCs), such that the HIO forms mature intestinal tissue. Also disclosed are methods for making a human intestinal tissue containing a functional enteric nervous system (ENS).

公开(公告)号：US11725183B2

公开(公告)日：2023-08-15

申请号：US16548280

申请日：2019-08-22

申请人： INSTITUT PASTEUR ,  FONDATION IMAGINE ,  ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS ,  UNIVERSITE PARIS DESCARTES ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (IN-SERM)

发明人： Gerard Eberl ,  David Bikard ,  Pamela Schnupf ,  Nadine Cerf Bensussan ,  Valerie Gaboriau-Routhiau ,  Philippe Sansonetti

IPC分类号： C12N1/20 ,  C12N15/74 ,  C12N13/00

CPC分类号： C12N1/20 ,  C12N13/00 ,  C12N15/74 ,  C12N2502/23

摘要： The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.

公开(公告)号：US20180224432A1

公开(公告)日：2018-08-09

申请号：US15819966

申请日：2017-11-21

申请人： EMULATE, Inc.

发明人： S. Jordan Kerns ,  Jenifer Obrigewitch ,  Michael Salmon ,  Magdalena Kasendra ,  Benjamin Richards Umiker

IPC分类号： G01N33/50 ,  B01L3/00 ,  C12N5/077 ,  C12N5/071

CPC分类号： C12M23/16 ,  B01L3/502753 ,  B01L2300/0681 ,  C07K16/2809 ,  C07K16/2818 ,  C12M25/02 ,  C12N5/0636 ,  C12N5/0652 ,  C12N5/0679 ,  C12N5/0697 ,  C12N2501/999 ,  C12N2502/13 ,  C12N2502/23 ,  C12N2502/28 ,  C12N2503/04 ,  C12N2533/90 ,  C12N2533/92 ,  G01N33/505 ,  G01N33/5088

摘要： An in vitro microfluidic gut-on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and gastrointestinal epithelial cells and endothelial cells. This in vitro microfluidic system can be used for modeling inflammatory gastrointestinal tissue, e.g., Crohn's disease, colitis and other inflammatory gastrointestinal disorders. These multicellular, layered microfluidic gut-on-chip further allow for comparisons between types of gastrointestinal tissues, e.g., small intestinal deuodejeum, small intestinal ileium, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic gut-on-chips allow identification of cells and cellular derived factors driving disease states and drug testing for reducing inflammation.

公开(公告)号：US20170349884A1

公开(公告)日：2017-12-07

申请号：US15400877

申请日：2017-01-06

申请人： Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

发明人： Jeffrey Michael Karp ,  Robert Samuel Langer ,  Xiaolei Yin

IPC分类号： C12N5/071 ,  G01N33/50

CPC分类号： C12N5/0678 ,  C12N5/0613 ,  C12N5/0679 ,  C12N2500/38 ,  C12N2500/62 ,  C12N2501/01 ,  C12N2501/065 ,  C12N2501/11 ,  C12N2501/119 ,  C12N2501/13 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/335 ,  C12N2501/395 ,  C12N2501/415 ,  C12N2501/42 ,  C12N2501/71 ,  C12N2501/72 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2502/23 ,  C12N2533/90 ,  G01N33/5008

摘要： A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK/ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.

公开(公告)号：US20170327794A1

公开(公告)日：2017-11-16

申请号：US15442991

申请日：2017-02-27

申请人： InCube Labs, LLC

发明人： Mir Imran

IPC分类号： C12N5/071 ,  A61K35/38

CPC分类号： A61K35/38 ,  A61K35/28 ,  C12N5/0679 ,  C12N2502/025 ,  C12N2502/03 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/23 ,  C12N2506/1346 ,  C12N2506/03

摘要： Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.